CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis.

ABSTRACT:

Background

Multiple sclerosis (MS) is an immune-mediated disease that damages myelin in the central nervous system (CNS). We investigated the profile of CCN3, a known regulator of immune function and a potential mediator of myelin regeneration, in multiple sclerosis in the context of disease state and disease-modifying treatment.

Methods

CCN3 expression was analysed in plasma, immune cells, CSF and brain tissue of MS patient groups and control subjects by ELISA, western blot, qPCR, histology and in situ hybridization.

Results

Plasma CCN3 levels were comparable between collective MS cohorts and controls but were significantly higher in progressive versus relapsing-remitting MS and between patients on interferon-β versus natalizumab. Higher body mass index was associate

SUBMITTER: Naughton M 

PROVIDER: S-EPMC7681974 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature